Abstract: Disclosed is a centralized cloud energy storage system for massive and distributed users and a transaction settlement method thereof, a storage medium, and a terminal. The system includes: a centralized energy storage facility invested and operated by a cloud energy storage service provider; the massive and distributed users; and a power network and a user energy management system connecting the centralized energy storage facility with the massive and distributed users. A user sends a charging and discharging request to the cloud energy storage service provider through the user energy management system, and the cloud energy storage service provider issues a charging and discharging instruction to the centralized cloud energy storage system.

Abstract: An antibacterial antiviral pharmaceutical composition, comprising the following raw materials in parts by weight: 4-14 parts of Herba pogostemonis, 9-28 parts of Rhizoma atractylodis, 5-18 parts of Herba elshoitziae, 11-33 parts of Folium artemisiae argyi, 0.1-3 parts of Flos caryophylli, and 2-10 parts of Herba menthae, and further comprising natural borneol and pharmaceutical adjuvants. The pharmaceutical composition can be prepared into medicinal volatile oil. The pharmaceutical composition and the volatile oil thereof can be used for resisting bacteria and viruses, clearing heat, reducing fever and/or treating respiratory diseases, and can be applied to the preparation of medicines for resisting SARS-CoV-2.

Abstract: Provided are an antibody binding to a TSLP protein or an antigen binding part thereof, a manufacturing method therefor and an application thereof. The antibody can bind to human TSLP and/or machine TSLP with high affinity, block the binding of TSLP and TSLPR, and inhibit the transduction of TSLP stimulus signals by means of an STAT5 pathway.

Abstract: The application discloses five polymorph forms B, P, F, J, O of (4-((R)-((2S,5R)-4-(3-fluorobenzyl)-(2,5-dimethylpiperazine-1-yl)(3-hydroxyphenyl)methyl)phenyl)(4-methylpiperidine-1-yl)methanone dihydrochloride, preparation methods thereof and application thereof in the manufacture of a medicament for preventing or treating a mood disorder or a disease related to a ? opioid receptor.

Abstract: The application discloses five polymorph forms B, P, F, J, O of (4-((R)-((2S,5R)-4-(3-fluorobenzyl)-(2,5-dimethylpiperazine-1-yl)(3-hydroxyphenyl)methyl)phenyl)(4-methylpiperidine-1-yl)methanone dihydrochloride, preparation methods thereof and application thereof in the manufacture of a medicament for preventing or treating a mood disorder or a disease related to a ? opioid receptor.

Abstract: The invention belongs to the field of medicine and chemical industry, and particularly relates to multiple crystal forms of scutellarin aglycone and preparation thereof. The invention also relates to use of said crystal forms of scutellarin aglycone in the manufacture of a medicament for preventing and/or treating a cardiovascular or cerebrovascular disease, rheumatic arthritis or stroke sequelae, etc. The crystal forms of scutellarin aglycone according to the invention have good stability, and can solve the problems concerning poor oral absorption and low bioavailability of scutellarin.

Abstract: The invention belongs to the field of medicine and chemical industry, and particularly relates to multiple crystal forms of scutellarin aglycone and preparation thereof. The invention also relates to use of said crystal forms of scutellarin aglycone in the manufacture of a medicament for preventing and/or treating a cardiovascular or cerebrovascular disease, rheumatic arthritis or stroke sequelae, etc. The crystal forms of scutellarin aglycone according to the invention have good stability, and can solve the problems concerning poor oral absorption and low bioavailability of scutellarin.